In November 2015, the Medicines Patent Pool (MPP) announced a licensing agreement with Bristol Myers Squibb (BMS) covering the direct-acting antiviral (DAA) drug daclatasvir (DAC), and its combinations. The agreement allows generic manufacture of the hepatitis C treatment for sale in at least 112 countries that together are home to 65.4% of people living with HCV in low- and middle-income countries. In addition to the countries in the Territory, DAC can be supplied into these additional countries:Albania, Argentina, Armenia, Belarus, Bosnia and Herzegovina, Brazil, Bulgaria, Chile, China, Colombia, Egypt, Jordan, Kazakhstan, Kosovo, Kyrgyzstan, Lebanon, Malaysia, Mexico, Moldova, Montenegro, North Macedonia, Peru, Romania, Serbia, Tajikistan, Thailand, Turkey, Ukraine, United Arab Emirates, Uruguay, and Venezuela. As of December 2021, generic daclatasvir can be supplied to at least 143 countries.
A technology transfer package is provided to all the sublicensees, but there is no obligation to use the technology. Information necessary for registration is also provided.
See related licence
Six sublicensees, namely Cipla, Hetero, Laurus, Mylan, Natco and Zydus Cadila have taken the technical decision not to rely on the licensed technology transfer package.
Quality assured formulations from MPP generic partners:
Click the logos to access the sublicensing agreements:
Sublicence Agreement
Legal
Access to Medicines Tracker
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.